Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Gynecologic 2Breast 2Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Vomiting 2Nausea 2Breast Neoplasms 2

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Duration of Therapy × Breast × Clear all
NCT00092183 2017-05-05

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Merck Sharp & Dohme LLC

Phase 4 Completed
866 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

NCT00092196 2017-05-05

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
820 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡